Chronic Obstructive Pulmonary Disease (COPD) is a complex pathological condition associated with an important reduction in physical activity and psychological problems that contribute to the patient's disability and poor health-related quality of life. Pulmonary rehabilitation is aimed to eliminate or at least attenuate these difficulties, mainly by promoting muscular reconditioning. The scope of this paper has been the analysis of the literature on pulmonary rehabilitation in COPD patients has appeared in the last five years, focusing on the principal outcomes obtained. The results demonstrate that pulmonary rehabilitation has a beneficial effect on dyspnoea relief, improving muscle strength and endurance. Moreover, pulmonary rehabilitation appears to be a highly effective and safe treatment for reducing hospital admissions mortality and improving health-related quality of life in COPD patients. It represents, therefore, a very important therapeutic option that, along with standard pharmachological therapy, can be used to obtain the best patient management. The favourable results obtained with pulmonary rehabilitation programs should stimulate researchers to improve our understanding of the mechanisms that form the basis of the beneficial effects of this therapeutic intervention. This would in turn increase the effectiveness of pulmonary rehabilitation in COPD patients. 1. Introduction Pulmonary rehabilitation is defined by the American Thoracic Society and the European Respiratory Society as an “evidence-based, multidisciplinary, and comprehensive intervention for patients with chronic respiratory diseases who are symptomatic and often have decreased daily life activities.” As such it is an integral part of the clinical management and health maintenance of those patients with chronic respiratory disease who remain symptomatic or continue to have decreased lung function despite standard medical treatment. Integrated into the individualised treatment of the patient, pulmonary rehabilitation is designed to reduce symptoms, optimise functional status, increase participation, and reduce health care costs by stabilising or reversing systemic manifestations of the disease [1]. All together these considerations underline the general implications and the importance of this respiratory treatment, which should be considered fundamental during the management of chronic obstructive pulmonary disease (COPD). In the last few years, medical literature has provided evidence that pulmonary rehabilitation favourably affects outcomes in COPD [2]. In spite of these
References
[1]
L. Nici, C. Donner, E. Wouters et al., “American thoracic society/European Respiratory Society statement on pulmonary rehabilitation,” The American Journal of Respiratory and Critical Care Medicine, vol. 173, no. 12, pp. 1390–1413, 2006.
S. Hurd, “The impact of COPD on lung health worldwide: epidemiology and incidence,” Chest, vol. 117, supplement 2, pp. 1S–4S, 2000.
[4]
R. O. Crapo, R. L. Jensen, and F. E. Hargreave, “Airway inflammation in COPD: physiological outcome measures and induced sputum,” European Respiratory Journal, vol. 21, no. 41, pp. 19s–28s, 2003.
[5]
A. Aliverti and P. T. Macklem, “The major limitation to exercise performance in COPD is inadequate energy supply to the respiratory and locomotor muscles,” Journal of Applied Physiology, vol. 105, no. 2, pp. 749–751, 2008.
[6]
P. Santus, S. Centanni, M. Verga, F. Di Marco, M. G. Matera, and M. Cazzola, “Comparison of the acute effect of tiotropium versus a combination therapy with single inhaler budesonide/formoterol on the degree of resting pulmonary hyperinflation,” Respiratory Medicine, vol. 100, no. 7, pp. 1277–1281, 2006.
[7]
E. D'Angelo, P. Santus, M. F. Civitillo, S. Centanni, and M. Pecchiari, “Expiratory flow-limitation and heliox breathing in resting and exercising COPD patients,” Respiratory Physiology and Neurobiology, vol. 169, no. 3, pp. 291–296, 2009.
[8]
D. E. O'Donnell and K. A. Webb, “Exertional breathlessness in patients with chronic airflow limitation: the role of lung hyperinflation,” The American Review of Respiratory Disease, vol. 148, no. 5, pp. 1351–1357, 1993.
[9]
D. E. O'Donnell, S. M. Revill, and K. A. Webb, “Dynamic hyperinflation and exercise intolerance in chronic obstructive pulmonary disease,” The American Journal of Respiratory and Critical Care Medicine, vol. 164, no. 5, pp. 770–777, 2001.
[10]
M. Decramer, V. de Bock, and R. Dom, “Functional and histologic picture of steroid-induced myopathy in chronic obstructive pulmonary disease,” The American Journal of Respiratory and Critical Care Medicine, vol. 153, no. 6, pp. 1958–2196, 1996.
[11]
F. Di Marco, M. Verga, M. Reggente et al., “Anxiety and depression in COPD patients: the roles of gender and disease severity,” Respiratory Medicine, vol. 100, no. 10, pp. 1767–1774, 2006.
[12]
T. L. Mills, “Comorbid depressive symptomatology: isolating the effects of chronic medical conditions on self-reported depressive symptoms among community-dwelling older adults,” Social Science and Medicine, vol. 53, no. 5, pp. 569–578, 2001.
[13]
A. Bellone, L. Spagnolatti, M. Massobrio et al., “Short-term effects of expiration under positive pressure in patients with acute exacerbation of chronic obstructive pulmonary disease and mild acidosis requiring non-invasive positive pressure ventilation,” Intensive Care Medicine, vol. 28, no. 5, pp. 581–585, 2002.
[14]
American Thoracic Society, “Pulmonary rehabilitation: official statement of the American Thoracic Society Board of Directors,” The American Journal of Respiratory Critical and Care Medicine, vol. 159, pp. 1666–1682, 1999.
[15]
D. E. O'Donnell, P. Hernandez, S. Aaron et al., “Canadian Thoracic Society COPD Guidelines: summary of highlights for family doctors,” Canadian Respiratory Journal, vol. 10, no. 4, pp. 183–185, 2003.
[16]
R. A. Pauwels, A. S. Buist, P. M. A. Calverley, C. R. Jenkins, and S. S. Hurd, “Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: National Heart, Lung, and Blood Institute and World Health Organization Global Initiative for Chronic Obstructive Lung Disease (GOLD): executive summary,” Respiratory Care, vol. 46, no. 8, pp. 798–825, 2001.
[17]
T. Troosters, C. F. Donner, A. M. W. J Schols, et al., “Rehabilitation in chronic obstructive pulmonary disease,” European Respiratory Monograph, vol. 38, pp. 337–358, 2006.
[18]
P. Ergün, D. Kaymaz, E. Günay et al., “Comprehensive out-patient pulmonary rehabilitation: treatment outcomes in early and late stages of chronic obstructive pulmonary disease,” Annals of Thoracic Medicine, vol. 6, no. 2, pp. 70–76, 2011.
[19]
J. Moore, H. Fiddler, J. Seymour et al., “Effect of a home exercise video programme in patients with chronic obstructive pulmonary disease,” Journal of Rehabilitation Medicine, vol. 41, no. 3, pp. 195–200, 2009.
[20]
A. T. Chang, T. Haines, C. Jackson et al., “Rationale and design of the PRSM study: pulmonary rehabilitation or self management for chronic obstructive pulmonary disease (COPD), what is the best approach?” Contemporary Clinical Trials, vol. 29, no. 5, pp. 796–800, 2008.
[21]
C. R. Van Wetering, M. Hoogendoorn, S. J. M. Mol, M. P. M. H. Rutten-Van M？lken, and A. M. Schols, “Short- and long-term efficacy of a community-based COPD management programme in less advanced COPD: a randomised controlled trial,” Thorax, vol. 65, no. 1, pp. 7–13, 2010.
[22]
K. Murphy, D. Casey, D. Devane et al., “A cluster randomised controlled trial evaluating the effectiveness of a structured pulmonary rehabilitation education programme for improving the health status of people with chronic obstructive pulmonary disease (COPD): the PRINCE Study protocol,” BMC Pulmonary Medicine, vol. 11, article 4, 2011.
[23]
D. van Ranst, H. Otten, J. W. Meijer, and A. J. van't Hul, “Outcome of pulmonary rehabilitation in COPD patients with severely impaired health status,” International Journal of Chronic Obstructive Pulmonary Disease, vol. 6, no. 1, pp. 647–657, 2011.
[24]
K. Yoshimi, J. Ueki, K. Seyama et al., “Pulmonary rehabilitation program including respiratory conditioning for chronic obstructive pulmonary disease (COPD): improved hyperinflation and expiratory flow during tidal breathing,” Journal of Thoracic Disease, vol. 4, no. 3, pp. 259–264, 2012.
[25]
M. J. Fischer, M. Scharloo, J. Abbink et al., “Concerns about exercise are related to walk test results in pulmonary rehabilitation for patients with COPD,” International Journal of Behavioral Medicine, vol. 19, no. 1, pp. 39–47, 2012.
[26]
N. S. Gale, J. M. Duckers, S. Enright, J. R. Cockcroft, D. J. Shale, and C. E. Bolton, “Does pulmonary rehabilitation address cardiovascular risk factors in patients with COPD?” BMC Pulmonary Medicine, vol. 11, article 20, 2011.
[27]
G. G. Riario-Sforza, C. Incorvaia, F. Paterniti et al., “Effects of pulmonary rehabilitation on exercise capacity in patients with COPD: a number needed to treat study,” International Journal of Chronic Obstructive Pulmonary Disease, vol. 4, pp. 315–319, 2009.
[28]
K. Enfield, S. Gammon, J. Floyd et al., “Six-minute walk distance in patients with severe end-stage COPD: association with survival after inpatient pulmonary rehabilitation,” Journal of Cardiopulmonary Rehabilitation and Prevention, vol. 30, no. 3, pp. 195–202, 2010.
[29]
I. B. Cheikh Rejbi, Y. Trabelsi, A. Chouchene et al., “Changes in six-minute walking distance during pulmonary rehabilitation in patients with COPD and in healthy subjects,” International Journal of Chronic Obstructive Pulmonary Disease, vol. 5, pp. 209–215, 2010.
[30]
A. S. Scott, M. A. Baltzan, J. Fox, and N. Wolkove, “Success in pulmonary rehabilitation in patients with chronic obstructive pulmonary disease,” Canadian Respiratory Journal, vol. 17, no. 5, pp. 219–223, 2010.
[31]
D. Stav, M. Raz, and I. Shpirer, “Three years of pulmonary rehabilitation: inhibit the decline in airflow obstruction, improves exercise endurance time, and body-mass index, in chronic obstructive pulmonary disease,” BMC Pulmonary Medicine, vol. 9, article 26, 2009.
[32]
B. G. Steele, B. Belza, K. C. Cain et al., “A randomized clinical trial of an activity and exercise adherence intervention in chronic pulmonary disease,” Archives of Physical Medicine and Rehabilitation, vol. 89, no. 3, pp. 404–412, 2008.
[33]
T. Eaton, P. Young, W. Fergusson et al., “Does early pulmonary rehabilitation reduce acute health-care utilization in COPD patients admitted with an exacerbation? A randomized controlled study,” Respirology, vol. 14, no. 2, pp. 230–238, 2009.
[34]
A. El？i, S. B？rek？i, N. Ovayolu, and O. Elbek, “The efficacy and applicability of a pulmonary rehabilitation programme for patients with COPD in a secondary-care community hospital,” Respirology, vol. 13, no. 5, pp. 703–707, 2008.
[35]
V. Gottlieb, A. M. Lyngs？, B. Nybo, et al., “RehabilItation for moderate COPD (GOLD 2) does it have an effect?” Chronic Obstructive Pulmonary Disease, vol. 8, pp. 380–386, 2011.
[36]
R. Sabit, T. L. Griffiths, A. J. Watkins et al., “Predictors of poor attendance at an outpatient pulmonary rehabilitation programme,” Respiratory Medicine, vol. 102, no. 6, pp. 819–824, 2008.
[37]
R. S. Goldstein, E. H. Gort, D. Stubbing, M. A. Avendano, and G. H. Guyatt, “Randomised controlled trial of respiratory rehabilitation,” The Lancet, vol. 344, no. 8934, pp. 1394–1397, 1994.
[38]
A. L. Ries, R. M. Kaplan, T. M. Limberg, and L. M. Prewitt, “Effects of pulmonary rehabilitation on physiologic and psychosocial outcomes in patients with chronic obstructive pulmonary disease,” Annals of Internal Medicine, vol. 122, no. 11, pp. 823–832, 1995.
[39]
P. J. Wijkstra, T. W. van der Mark, J. Kraan, R. van Altena, G. H. Ko？ter, and D. S. Postma, “Effects of home rehabilitation on physical performance in patients with chronic obstructive pulmonary disease (COPD),” European Respiratory Journal, vol. 9, no. 1, pp. 104–110, 1996.
[40]
T. A. R. Seemungal, G. C. Donaldson, E. A. Paul, J. C. Bestall, D. J. Jeffries, and J. A. Wedzicha, “Effect of exacerbation on quality of life in patients with chronic obstructive pulmonary disease,” The American Journal of Respiratory and Critical Care Medicine, vol. 157, no. 5, pp. 1418–1422, 1998.
[41]
J. R. Hurst, J. Vestbo, A. Anzueto et al., “Susceptibility to exacerbation in chronic obstructive pulmonary disease,” The New England Journal of Medicine, vol. 363, no. 12, pp. 1128–1138, 2010.
[42]
P. J. Wijkstra and J. H. Strijbos, “Home-based rehabilitation for patients with chronic obstructive pulmonary disease,” Monaldi Archives for Chest Disease, vol. 53, no. 4, pp. 450–453, 1998.
[43]
P. J. Wijkstra, “Home based rehabilitation for patients with COPD. Is it equally effective as compared to outpatient rehabilitation?” Monaldi Archives for Chest Disease, vol. 59, no. 4, pp. 335–337, 2003.
[44]
R. Reina-Rosenbaum, J. R. Bach, and J. Penek, “The cost/benefits of outpatient-based pulmonary rehabilitation,” Archives of Physical Medicine and Rehabilitation, vol. 78, no. 3, pp. 240–244, 1997.
[45]
P. J. Wijkstra, J. H. Strijbos, and G. H. K？ter, “Home-based rehabilitation for patients with COPD: organization, effects and financial implications,” Monaldi Archives for Chest Disease, vol. 55, no. 2, pp. 130–134, 2000.
[46]
C. Hernandez, A. Casas, J. Escarrabill et al., “Home hospitalisation of exacerbated chronic obstructive pulmonary disease patients,” European Respiratory Journal, vol. 21, no. 1, pp. 58–67, 2003.
[47]
P. J. Wijkstra, T. W. van der Mark, J. Kraan, R. van Altena, G. H. Ko？ter, and D. S. Postma, “Long-term effects of home rehabilitation on physical performance in chronic obstructive pulmonary disease,” The American Journal of Respiratory and Critical Care Medicine, vol. 153, no. 4, pp. 1234–1241, 1996.
[48]
N. Ambrosino and S. Strambi, “New strategies to improve exercise tolerance in chronic obstructive pulmonary disease,” European Respiratory Journal, vol. 24, no. 2, pp. 313–322, 2004.
[49]
Y. Lacasse, R. Goldstein, T. J. Lasserson, and S. Martin, “Pulmonary rehabilitation for chronic obstructive pulmonary disease (review),” The Cochrane Library, no. 3, 2009.
[50]
C. R. Osadnik, C. F. McDonald, and A. P. Jones, “Airway clearance techniques for chronic obstructive pulmonary disease (review),” Cochrane Database of Systematic Reviews, vol. 3, Article ID CD008328, 2012.
[51]
G. Piatti, U. Ambrosetti, P. Santus, and L. Allegra, “Effects of salmeterol on cilia and mucus in COPD and pneumonia patients,” Pharmacological Research, vol. 51, no. 2, pp. 165–168, 2005.
[52]
P. Santus, S. Picciolo, A. Proietto et al., “Doctor-patient relationship: a resource to improve respiratory diseases management,” European Journal of Internal Medicine, vol. 23, no. 5, pp. 442–446, 2012.
[53]
M. Cazzola, P. Santus, F. Di Marco et al., “Bronchodilator effect of an inhaled combination therapy with salmeterol plus fluticasone and formeterol plus budesonide in patients with COPD,” Respiratory Medicine, vol. 97, no. 5, pp. 453–457, 2003.
[54]
M. A. Puhan, E. Gimeno-Santos, M. Scharplatz, T. Troosters, E. H. Walters, and J. Steurer, “Pulmonary rehabilitation following exhacerbations of chronic obstructive pulmonary disease (review),” The Cochrane Library, 2011.
